Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab plus fludarabine and cyclophosphamide in relapsed or refractory Waldenström’s macroglobulinemia
2012-004998-53Phase 2Active
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in Waldenström macroglobulinemia (WM), sponsored by National and Kapodistrian University of Athens. Primary endpoint: Overall response rate (ORR). Started Jan 2013; status: active.
02
Drugs
ofatumumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2012-004998-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004998-53.